ARC-520 Injection

DRUG3 trials

Sponsors

Arrowhead Pharmaceuticals

Conditions

Chronic Hepatitis BHepatitis B

Phase 2

Study of ARC-520 in Patient With Chronic Hepatitis B Virus

WithdrawnNCT02349126

Arrowhead PharmaceuticalsChronic Hepatitis B

Start: 2015-02-28End: 2016-03-31Updated: 2025-12-26

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

TerminatedNCT02604199

Arrowhead PharmaceuticalsHepatitis B

Start: 2015-09-30End: 2017-01-31Updated: 2026-01-13

Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

TerminatedNCT02738008

Arrowhead PharmaceuticalsHepatitis B

Start: 2016-03-31End: 2016-12-31Updated: 2026-01-13